ABACAVIR AND LAMIVUDINE

Pre-Launch

abacavir; lamivudine

Viatris (2)
NDAORAL SUSPENSIONTABLET
Lifecycle
Pre-Launch
Clinical Trials
1

Mechanism of Action

HIV-1 [see ] .

Indications (2)

human immunodeficiency virus type 1 (HIV-1) infectioncombination with other antiretroviral agents for the treatment of HIV-1 infection

Clinical Trials (1)

NCT00094367Phase 3Completed

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

Started Jul 2004
900 enrolled
HIV Infection
Company
Viatris (2)
Viatris (2)
China - Shanghai
292 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers